DK2258344T3 - Fast farmaceutisk doseringsform omfattende en fast dispersion af ritonavir og lopinavir - Google Patents

Fast farmaceutisk doseringsform omfattende en fast dispersion af ritonavir og lopinavir

Info

Publication number
DK2258344T3
DK2258344T3 DK10181250.1T DK10181250T DK2258344T3 DK 2258344 T3 DK2258344 T3 DK 2258344T3 DK 10181250 T DK10181250 T DK 10181250T DK 2258344 T3 DK2258344 T3 DK 2258344T3
Authority
DK
Denmark
Prior art keywords
dosage form
solid
pharmaceutical dosage
lopinavir
ritonavir
Prior art date
Application number
DK10181250.1T
Other languages
English (en)
Inventor
Gunther Berndl
Joerg Breitenbach
Laman Alani
Soumojeet Ghosh
Joerg Rosenberg
Ulrich Reinhold
Bernd Liepold
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34217089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2258344(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK2258344T3 publication Critical patent/DK2258344T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
DK10181250.1T 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende en fast dispersion af ritonavir og lopinavir DK2258344T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/650,178 US20050048112A1 (en) 2003-08-28 2003-08-28 Solid pharmaceutical dosage form
EP04816820A EP1663183B9 (en) 2003-08-28 2004-08-23 Solid pharmaceutical dosage form comprising ritonavir

Publications (1)

Publication Number Publication Date
DK2258344T3 true DK2258344T3 (da) 2013-01-02

Family

ID=34217089

Family Applications (5)

Application Number Title Priority Date Filing Date
DK15169378.5T DK2942051T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform der omfatter en fast dispersion af hiv-protease-inhibitor
DK10181264.2T DK2258345T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende en fast dispersion af en HIV-proteaseinhibitor
DK04816820.7T DK1663183T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende ritonavir
DK10181250.1T DK2258344T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende en fast dispersion af ritonavir og lopinavir
DK10181268.3T DK2258346T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende en fast dispersion af en hiv-proteaseinhibitor

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK15169378.5T DK2942051T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform der omfatter en fast dispersion af hiv-protease-inhibitor
DK10181264.2T DK2258345T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende en fast dispersion af en HIV-proteaseinhibitor
DK04816820.7T DK1663183T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende ritonavir

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10181268.3T DK2258346T3 (da) 2003-08-28 2004-08-23 Fast farmaceutisk doseringsform omfattende en fast dispersion af en hiv-proteaseinhibitor

Country Status (31)

Country Link
US (1) US20050048112A1 (da)
EP (6) EP2258345B1 (da)
JP (6) JP4815348B2 (da)
KR (5) KR20150044031A (da)
CN (5) CN105106104A (da)
AT (1) ATE516017T1 (da)
AU (3) AU2004283087C1 (da)
CA (2) CA2536638C (da)
CR (3) CR8256A (da)
CY (5) CY1111981T1 (da)
DK (5) DK2942051T3 (da)
EA (4) EA201890737A3 (da)
EC (1) ECSP066397A (da)
ES (5) ES2653762T3 (da)
HK (4) HK1094766A1 (da)
HR (1) HRP20110555T1 (da)
HU (3) HUE031153T2 (da)
IL (3) IL173939A (da)
ME (2) MEP17608A (da)
MX (2) MXPA06002346A (da)
NO (3) NO330282B1 (da)
NZ (2) NZ545499A (da)
PL (5) PL1663183T3 (da)
PT (5) PT2942051T (da)
RS (2) RS59969B1 (da)
SG (3) SG179401A1 (da)
SI (5) SI2942051T1 (da)
TW (1) TWI342221B (da)
UA (1) UA85564C2 (da)
WO (1) WO2005039551A2 (da)
ZA (3) ZA200801362B (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
AU2012202831B2 (en) * 2005-02-23 2015-01-22 Abbvie Inc. A solid pharmaceutical dosage formulation
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
EP2051703B1 (en) * 2005-12-14 2010-07-21 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
KR20080089344A (ko) * 2005-12-14 2008-10-06 에프. 호프만-라 로슈 아게 Ｃ형 간염 바이러스(ｈｃｖ) 전구약물 제형
US20090136570A1 (en) * 2006-01-20 2009-05-28 Bhagwant Rege Taste-Masked Tablets and Granules
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
TW200815033A (en) * 2006-08-10 2008-04-01 Cipla Ltd Antiretroviral solid oral composition
WO2008067164A2 (en) 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
US9891239B2 (en) 2007-02-23 2018-02-13 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
US20100021540A1 (en) * 2008-02-28 2010-01-28 Abbott Laboratories Tablets and Preparation Thereof
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
CN102238945B (zh) * 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TWI471321B (zh) 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
EP2279728A1 (en) 2009-07-31 2011-02-02 Ranbaxy Laboratories Limited Solid dosage forms of HIV protease inhibitors
WO2011013110A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2012120541A2 (en) * 2011-03-07 2012-09-13 Hetero Research Foundation Amorphous form of lopinavir and ritonavir mixture
CA2837266A1 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
WO2013025449A1 (en) * 2011-08-16 2013-02-21 Merck Sharp & Dohme Corp. Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
EP2564832A1 (en) 2011-08-29 2013-03-06 Hexal AG Solid dosage form of HIV protease inhibitors
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
US20150111909A1 (en) * 2012-03-07 2015-04-23 Ratiopharm Gmbh Dosage form comprising non-crystalline lopinavir and crystalline ritonavir
EP2822554B1 (en) 2012-03-07 2016-05-18 ratiopharm GmbH Dosage form comprising lopinavir and ritonavir
CN103655571B (zh) * 2012-09-11 2016-04-20 上海星泰医药科技有限公司 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
EP2911651B1 (en) 2012-09-27 2016-06-22 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
EP2900219B1 (en) 2012-09-27 2016-07-06 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
RU2505286C1 (ru) 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2543322C1 (ru) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
US20190038754A1 (en) * 2017-08-07 2019-02-07 SE Tylose, USA, Inc. Pharmaceutical composition in solid extruded form
US20190269662A1 (en) * 2018-03-02 2019-09-05 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
CN108186578A (zh) * 2018-03-27 2018-06-22 聊城大学 一种利托那韦固体分散体的制备方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
CN113318076B (zh) * 2021-06-02 2022-09-23 聊城大学 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法
CN114557967B (zh) * 2022-03-17 2023-06-02 乐普制药科技有限公司 一种利托那韦固体分散体的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5542206A (en) 1994-10-11 1996-08-06 Lisch; Albert Lure and tackle stacking container
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
DE19841244A1 (de) * 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
SI1183026T1 (sl) 1999-06-04 2006-10-31 Abbott Lab Izboljsane farmacevtske spojine, vsebujoce ritonavir
DE60017444T2 (de) 1999-11-12 2006-02-09 Abbott Laboratories, Abbott Park Pharmazeutische formulierungen auf basis fester dispersionen
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
AU2002304387A1 (en) 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
CA2474838C (en) * 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
DE10213242A1 (de) 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
WO2008067164A2 (en) 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations

Also Published As

Publication number Publication date
ES2653762T3 (es) 2018-02-08
HUE035985T2 (hu) 2018-06-28
PT2258345T (pt) 2017-01-20
KR101457967B1 (ko) 2014-11-07
SG145690A1 (en) 2008-09-29
RS20181262A1 (sr) 2019-02-28
CR20120662A (es) 2013-03-13
PL1663183T3 (pl) 2011-10-31
SI2258345T1 (sl) 2017-01-31
AU2010238573A1 (en) 2010-11-18
JP5395125B2 (ja) 2014-01-22
DK1663183T3 (da) 2011-08-29
CN102772380B (zh) 2015-08-19
AU2007249115A1 (en) 2008-01-10
WO2005039551A2 (en) 2005-05-06
CR20120661A (es) 2013-03-13
TWI342221B (en) 2011-05-21
CN101919858A (zh) 2010-12-22
RS59969B1 (sr) 2020-03-31
EP2258345A3 (en) 2011-01-19
IL173939A0 (en) 2006-07-05
PT2258344E (pt) 2013-02-18
ES2399810T3 (es) 2013-04-03
JP2011236232A (ja) 2011-11-24
KR20060121837A (ko) 2006-11-29
EA201301045A1 (ru) 2014-05-30
PT2258346T (pt) 2017-10-24
ZA200801361B (en) 2011-11-30
EA200900292A1 (ru) 2009-06-30
NO20061342L (no) 2006-05-29
PL2258345T3 (pl) 2017-03-31
AU2010238573B2 (en) 2012-12-13
NO20131743L (no) 2006-05-29
CY1119651T1 (el) 2018-04-04
DK2258345T3 (da) 2017-01-16
ZA200601718B (en) 2009-11-25
EP2258345B1 (en) 2016-09-21
CA2689639C (en) 2014-06-10
CN102764244A (zh) 2012-11-07
MX358033B (es) 2018-08-02
KR101132602B1 (ko) 2012-04-06
HUE031153T2 (en) 2017-07-28
NO335326B1 (no) 2014-11-10
KR101563222B1 (ko) 2015-10-26
SI2258344T1 (sl) 2013-03-29
IL254581A0 (en) 2017-11-30
EP1663183B1 (en) 2011-07-13
SI2942051T1 (en) 2018-06-29
SG10201507902UA (en) 2015-10-29
KR20150044031A (ko) 2015-04-23
ES2608720T3 (es) 2017-04-12
JP5498411B2 (ja) 2014-05-21
NO334418B1 (no) 2014-03-03
CY1118505T1 (el) 2017-07-12
CY1113596T1 (el) 2016-06-22
DK2942051T3 (da) 2018-05-07
JP2018035163A (ja) 2018-03-08
EA201890737A2 (ru) 2018-08-31
EA011924B1 (ru) 2009-06-30
RS20060140A (en) 2008-09-29
CN102772380A (zh) 2012-11-14
KR20140046078A (ko) 2014-04-17
KR20120054666A (ko) 2012-05-30
NZ545499A (en) 2009-11-27
MXPA06002346A (es) 2006-05-19
CA2536638C (en) 2010-04-06
EP2258344B1 (en) 2012-11-14
CY1111981T1 (el) 2015-11-04
ES2367173T3 (es) 2011-10-31
JP2011126898A (ja) 2011-06-30
ES2666390T3 (es) 2018-05-04
RS57663B1 (sr) 2018-11-30
SI2258346T1 (sl) 2017-12-29
SI1663183T1 (sl) 2011-09-30
TW200522979A (en) 2005-07-16
PL2942051T3 (pl) 2018-07-31
ATE516017T1 (de) 2011-07-15
IL207260A (en) 2017-10-31
PL2258346T3 (pl) 2018-01-31
EP2942051A1 (en) 2015-11-11
UA85564C2 (ru) 2009-02-10
DK2258346T3 (da) 2017-11-13
EP2258344A3 (en) 2011-01-19
IL173939A (en) 2017-03-30
AU2004283087B2 (en) 2007-09-20
NZ579622A (en) 2011-01-28
JP2016094433A (ja) 2016-05-26
ME00130B (me) 2010-10-10
CA2689639A1 (en) 2005-05-06
JP2007504142A (ja) 2007-03-01
NO20100367L (no) 2006-05-29
CY1120138T1 (el) 2018-12-12
ECSP066397A (es) 2006-08-30
US20050048112A1 (en) 2005-03-03
JP5903413B2 (ja) 2016-04-13
SG179401A1 (en) 2012-04-27
EP2258344A2 (en) 2010-12-08
MEP17608A (en) 2010-06-10
EP2258346A2 (en) 2010-12-08
EA033224B1 (ru) 2019-09-30
KR101281994B1 (ko) 2013-07-04
HK1217298A1 (zh) 2017-01-06
AU2004283087A1 (en) 2005-05-06
EP2258346B1 (en) 2017-09-27
EP2942051B1 (en) 2018-01-17
EP1663183B9 (en) 2012-06-13
HK1257502A1 (zh) 2019-10-25
PT2942051T (pt) 2018-04-23
HK1094766A1 (en) 2007-04-13
EP1663183A2 (en) 2006-06-07
EP2258346A3 (en) 2011-01-19
CN1901884A (zh) 2007-01-24
EP3354261A1 (en) 2018-08-01
EA201890737A3 (ru) 2019-01-31
CN1901884B (zh) 2012-07-25
CN105106104A (zh) 2015-12-02
HRP20110555T1 (hr) 2011-09-30
HK1145969A1 (en) 2011-05-13
ZA200801362B (en) 2009-03-25
EA200600473A1 (ru) 2006-10-27
JP2013241460A (ja) 2013-12-05
JP4815348B2 (ja) 2011-11-16
CA2536638A1 (en) 2005-05-06
PT1663183E (pt) 2011-08-25
KR20110122771A (ko) 2011-11-10
HUE038792T2 (hu) 2018-11-28
EP2258345A2 (en) 2010-12-08
EA020992B1 (ru) 2015-03-31
NO330282B1 (no) 2011-03-21
CR8256A (es) 2008-01-11
WO2005039551A3 (en) 2006-08-03
AU2007249115B2 (en) 2010-08-12
CN101919858B (zh) 2013-10-30
AU2004283087C1 (en) 2008-04-24
PL2258344T3 (pl) 2013-04-30

Similar Documents

Publication Publication Date Title
DK2258344T3 (da) Fast farmaceutisk doseringsform omfattende en fast dispersion af ritonavir og lopinavir